Heron Therapeutics (NASDAQ: HRTX) is one of 196 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its peers? We will compare Heron Therapeutics to similar businesses based on the strength of its dividends, analyst recommendations, institutional ownership, valuation, risk, profitability and earnings.

Profitability

This table compares Heron Therapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Heron Therapeutics N/A -451.80% -152.23%
Heron Therapeutics Competitors -3,991.09% -119.71% -44.31%

Earnings & Valuation

This table compares Heron Therapeutics and its peers gross revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Heron Therapeutics $13.42 million -$174.14 million -3.87
Heron Therapeutics Competitors $207.80 million -$2.20 million 0.00

Heron Therapeutics’ peers have higher revenue and earnings than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Heron Therapeutics has a beta of 2.12, indicating that its share price is 112% more volatile than the S&P 500. Comparatively, Heron Therapeutics’ peers have a beta of 1.63, indicating that their average share price is 63% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Heron Therapeutics and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Heron Therapeutics 0 0 10 0 3.00
Heron Therapeutics Competitors 464 2209 6098 117 2.66

Heron Therapeutics presently has a consensus price target of $30.11, indicating a potential upside of 82.49%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 1.91%. Given Heron Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Heron Therapeutics is more favorable than its peers.

Insider and Institutional Ownership

47.0% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 19.9% of Heron Therapeutics shares are held by company insiders. Comparatively, 13.8% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company’s SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.